In short - the screening period could either cost or save you a bunch of money, depending on how you design it!
The duration of screening as described in the protocol is driven by the analysis and tests to be performed. Since those tests are variable in duration, often only an upper bound on this screening period is given, e.g. maximum 14 days. This contrasts with the rest of the visit schedule, which is usually less variable, e.g. patients are scheduled every 30 days ±3 days.
Over the past decade, clinical supplies chain management has significantly evolved with the ever-increasing trials complexity and pressure on costs. Quite a few vendors now propose professional, dedicated software solutions. In this post, I would like to propose one possible classification of these solutions and highlight the differences, oriented towards the depth and accuracy of calculations.